Company with Vail Valley investors signs marketing deal
Vail, CO Colorado
LONGMONT, Colorado – MicroPhage Inc., developers of diagnostic products for bacterial identification as well as antibiotic susceptibility and resistance testing, announced this week it has reached an agreement with Cardinal Health granting exclusive rights to market the “KeyPath MRSA/MSSA Blood Culture Test” product line in North America.
MicroPhage received a lot of financial help early on from “Alpine Angels,” a group of local investors founded by Gary Mesch, who has a home in the valley.
Under the marketing agreement, Cardinal Health has the exclusive distribution rights to MicroPhage’s first testing equipment and other products now in development for testing blood culture specimens for Staphylococcus aureus, in the U.S., Canada and U.S. territories. In exchange for these rights Cardinal Health has provided MicroPhage with operational funding for development and commercialization of new products.
“We are very pleased to have Cardinal Health as our exclusive marketing partner in the U.S. and Canada,” said Don Mooney, president of MicroPhage. “Their outstanding reputation and presence in U.S. hospitals affords MicroPhage the greatest opportunity for success with the launch of its first diagnostic test.”
To learn more, go to http://www.microphage.com.